Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024

Quality Of Top Five Financings Bodes Well

Jan 05 2024

• By Mandy Jackson

Internet, business, Technology and network concept. Venture capital. Investor capital. — Q4 VC funding fell from Q3, but smaller deals rebounded • Source: Shutterstock

Related Content

Finance Watch: Venture Capital Dominates Biopharma Funding So Far In 2022

Jun 03 2022

Deal Watch: Novartis Partners In CNS Gene Therapies A Second Time With Voyager

Jan 02 2024

BMS Makes Second Big Buy Of December, Pays $4.1bn For RayzeBio

Dec 27 2023

BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy

Dec 22 2023

Finance Watch: The Rush To End 2023 With Fresh VC Cash For Biopharma

Dec 20 2023

Bicara Scoops Up $165m And Heads To Pivotal Trials

Dec 13 2023

AbbVie Strikes Again By Teeing Up $8.7bn Offer For Cerevel

Dec 06 2023

Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds

Nov 10 2023

Finance Watch: Aiolos Launches With $245m Series A; OrbiMed’s New Funds Total $4.3bn

Oct 24 2023

Q3 Shows Ongoing Venture Fundraising Challenges In Tough Financial Market

Oct 05 2023

Biopharma Investors, Companies Learning To Adjust To Financial Market Realities

Jun 27 2023

Related Companies

Bristol Myers Squibb Company

Karuna Therapeutics, Inc.

RayzeBio, Inc.

ImmunoGen, Inc.

Cerevel Therapeutics Holdings, Inc.

MapLight Therapeutics

Terremoto Biosciences, Inc.

Bicara Therapeutics, Inc.

Additional Topics

Financing Evaluate Data StartUps and SMEs Deals Commercial BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window